alosetron / Generic mfg. - LARVOL DELTA

DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME TREATMENT OPTIONS ELUXADOLINE, RIFAXIMIN, AND ALOSETRON: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE (DDW 2025) - "Conclusion : Our analysis of the FAERS database showed frequent reports of abdominal pain, constipation, and nausea/vomiting related to the three FDA approved medications for IBS-D. Each raised concerns for distinct and serious AEs including pancreatitis (eluxadoline), C. difficile infection (rifaximin), ischemic colitis (alosetron), and intestinal obstruction/perforation (alosetron)."

Adverse events • Constipation • Gastrointestinal Disorder • Immunology • Infectious Disease • Pain • Pancreatitis

EVALUATING THE SAFETY OF PHARMACOTHERAPY FOR IRRITABLE BOWEL SYNDROME: A META-ANALYSIS (DDW 2025) - "AEs were more varied for tricyclics (indicated for IBS global symptoms); for example, compared to placebo the three most common AEs with associated risk increases were drowsiness (14%), dry mouth (12%), and weight gain (9%) for amitriptyline, dry mouth (22%), flushing (18%), and constipation (17%) for desipramine, and fatigue (15%), dry mouth (3%) and blurry vision (1.5%) for doxepin...The NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor (indicated for IBS-C) was 27 (p < 0.01), 53 (p = 0.59), 58 (p < 0.01), 59 (p = 0.03), and 17 (p <0.01) respectively. The NNH for alosetron and eluxadoline (indicated for IBS-D) was 16 (p < 0.01) and 32 (p < 0.01). Ramosetron and rifaximin (indicated for IBS-D) had a negative risk difference, with the rate of withdrawal due to AEs higher in the placebo arm, so NNH was a negative, although statistically insignificant, value... Tricyclics, alosetron, and tenapanor are associated with a higher..."

Retrospective data • Constipation • Fatigue • Gastrointestinal Disorder • Xerostomia

Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database. (PubMed, Expert Opin Drug Saf) - "Our analysis of the FAERS database showed frequentreports of abdominal pain, constipation, and nausea/vomiting related to thethree FDA approved medications for IBS-D. Each raised concerns for distinct andserious AEs including pancreatitis (eluxadoline), C. difficileinfection (rifaximin), ischemic colitis (alosetron), and intestinalobstruction/perforation (alosetron)."

Adverse events • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain • Pancreatitis

Comparison chart: Safety of drugs for IBS in pregnancy and lactation. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastrointestinal Disorder

Drugs for irritable bowel syndrome. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison chart: Some drugs for irritable bowel syndrome with diarrhea (IBS-D). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastrointestinal Disorder

Figure 1: Treatments for irritable bowel syndrome (IBS) in adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract. (PubMed, Aliment Pharmacol Ther) - "Scintigraphic CT measurement fulfils the expectation of a surrogate endpoint for symptom-based outcomes, particularly in IBS-D or IBS-C and CIC."

Journal • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

LOTRONEX (ALOSETRON HCL) RISK EVALUATION AND MITIGATION STRATEGY (REMS) (DDW 2024) - No abstract available

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Curious Case of Colitis. (PubMed, Gastroenterology) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new? (PubMed, Expert Opin Drug Metab Toxicol) - "PubMed, Google Scholar and the USFDA databases were searched up to November 2023 to identify and include all updated information on eluxadoline, alosetron, and rifaximin. Therefore, healthcare providers may need to reduce the dosage for female patients to address this gender-specific issue. Integrating IBS care into sustainable development efforts can indirectly contribute to achieving SDGs and promote health and well-being for all."

Journal • PK/PD data • Review • Gastrointestinal Disorder • Metabolic Disorders

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs. (PubMed, Expert Opin Investig Drugs) - "Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed...Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment."

Journal • Review • Gastrointestinal Disorder • Inflammation

Differential roles of serotonin receptor subtypes in regulation of neurotrophin receptor expression and intestinal hypernociception. (PubMed, Histol Histopathol) - "Stronger analgesic effects by peroral CYY were observed compared with reference standards in two IBS-like mouse models. The 5-HT₇-dependent NTR upregulation and neurite elongation may be involved in intestinal hypernociception."

Journal • Addiction (Opioid and Alcohol) • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Pain • BDNF • NGF • NGFR • NTRK1 • NTRK2

Diagnosis and Management Utilization Amongst Veterans With IBS by IBS-Subtype and Provider Specialty (ACG 2023) - "The eligible cohort included 136 veterans, separated by subtype: IBS-diarrhea (48.9%), IBS-other (24.1%), IBS-mixed (18.0%), and IBS-constipation (9.0%). GI providers were more likely to recommend fiber and low FODMAP than primary care/non-GI providers (63.0% vs 28.6%, p< 0.0001 and 21.9% vs 6.4%, p=0.0141 respectively). Regarding IBS-D specific treatments, both GI and primary care/non-GI providers frequently followed recommendations related to alosetron use and avoidance of bile acid sequestrants, but they both had low practice utilization for rifaximin and mixed opioid agonist/antagonists."

Celiac Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • CRP

Gut microbiota alteration after cholecystectomy contributes to post-cholecystectomy diarrhea via bile acids stimulating colonic serotonin. (PubMed, Gut Microbes) - "Notably, diarrheal phenotypes in PCD mice were depleted by tryptophan hydroxylase 1 inhibitor (LX1606) and 5-HTRs selective antagonists (alosetron and GR113808). Intriguingly, blocking BAs-conjugated TGR5/TRPA1 signaling pathway could significantly alleviate PCD. In conclusion, altered gut microbiota after cholecystectomy contributes to PCD by promoting secondary BAs in colon, which stimulates colonic 5-HT and increases colon motility."

Journal • Gastrointestinal Disorder • Transplantation • TRPA1

Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome. (PubMed, FASEB Bioadv) - "The current findings demonstrated activation of brain regions to RD following DSS treatments which was not present in naïve macaques, suggesting visceral hypersensitivity. Brain activation in turn was reduced by alosetron, which could underlie the analgesic effect alosetron in IBS patients."

Journal • Preclinical • Anesthesia • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain

A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers. (PubMed, Adv Ther) - "Rifaximin, alosetron, and eluxadoline are effective treatments indicated for IBS-D, but have limited availability internationally. Psychological interventions may be effective in treating abdominal pain alone and global symptoms in IBS. We describe use of these diverse therapies and provide an overview to facilitate the primary care provider's approach to distinguishing IBS-D from other conditions with symptom overlap."

Journal • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. (PubMed, Gastroenterology) - "The panel agreed on 8 recommendations for the management of patients with IBS-D. The panel made conditional recommendations for eluxadoline, rifaximin, alosetron, (moderate certainty), loperamide (very low certainty), tricyclic antidepressants, and anstispasmodics (low certainty). The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty)."

Clinical guideline • Gastroenterology • Gastrointestinal Disorder • Immunology

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. (PubMed, United European Gastroenterol J) - "Regarding treatment, a strong consensus was achieved for the use of a diet low fermentable oligo-, di-, monosaccharides and polyols, gut-directed psychological therapies, rifaximin, loperamide, and eluxadoline. A weak or conditional recommendation was achieved for antispasmodics, probiotics, tryciclic antidepressants, bile acid sequestrants, 5-hydroxytryptamine-3 antagonists (i.e. alosetron, ondansetron, or ramosetron). A multinational group of European experts summarized the current state of consensus on the definition, diagnosis, and management of IBS-D and FDr."

Clinical guideline • Journal • Review • Celiac Disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • CRP

Expression of the relaxin family peptide 4 receptor by enterochromaffin cells of the mouse large intestine. (PubMed, Cell Tissue Res) - "We used the RXFP4 agonist, INSL5-A13, to activate the receptor and probe the role of the 5-HT cells in which it is expressed. INSL5-A13 administered by i.p. injection to conscious mice caused an increase in colorectal propulsion that was antagonised by the 5-HT receptor blocker, alosetron, also given i.p. We conclude that stimuli that excite INSL5-containing colonic L-cells release INSL5 that, through RXFP4, excites 5-HT release from neighbouring endocrine cells, which in turn acts on 5-HT receptors of enteric sensory neurons to elicit propulsive reflexes."

Journal • Preclinical • Gastrointestinal Disorder

"And yeah: Luvox has a bunch of contraindications, such as - alosetron, dihydroergotamine isocarboxazid, Lonafarnib, ramelteon, selegiline, citalopram - uk what? Lemme just post the link bc its a lot: https://t.co/miBZdmTVV6" (@Syfx18637973)

In silico Repurposing of Drugs for pan-HDAC and pan-SIRT Inhibitors: Consensus Structure-based Virtual Screening and Pharmacophore Modeling Investigations. (PubMed, Turk J Pharm Sci) - "Based on the consensus scores, belinostat, bexarotene, and cianidanol emerged as top virtual pan-HDAC inhibitors whereas alosetron, cinacalcet, and indacaterol emerged as virtual pan-SIRT inhibitors. The consensus approach enabled selection of the best performing drug molecules according to different software, and good scores against isoforms (virtual pan-HDAC and pan-SIRT inhibitors). The study not only proposes potential drugs to be repurposed for HDAC and SIRT-related diseases but also provides insights for designing potent de novo derivatives."

Journal • Oncology • HDAC1 • SIRT1

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). (PubMed, Aliment Pharmacol Ther) - "The treatment of IBS-D/M ideally involves a multidisciplinary approach of primary care, gastroenterologist and psychologist. Treatment often involves both non-pharmacological and pharmacological therapies. Future therapies may include faecal microbial transplant, Crofelemer and serotonin antagonists, but further studies are needed."

Journal • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain • Transplantation

New approaches to ondansetron and alosetron inspire a versatile, flow photochemical method for indole synthesis. (PubMed, Chem Commun (Camb)) - "An oxidative photocyclisation of N-arylenaminones to indoles is described, that mirrors the Fischer indole synthesis but uses anilines in place of arylhydrazines. Its value is exemplified with new approaches to the WHO-listed APIs ondansetron and alosetron."

Journal

Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. (PubMed, Drugs) - "We performed a narrative review of the literature to summarize these important determinants of treatment choice including: labeled indications; clinical profiles of efficacy, safety, and tolerability of prescription drugs; and cost-effectiveness for diarrhea-predominant IBS drugs (IBS-D: alosetron, eluxadoline, and rifaximin) and constipation-predominant IBS drugs (IBS-C: linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor). We then review the standard model of shared decision-making aimed at guiding an informed, patient-centered discussion to integrate comparative clinical and cost outcomes toward choosing an IBS treatment in practice."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology